This inventor holds 2 USPTO granted patents. Top assignees: Basilea Pharmaceutica Ag, Ruprecht-Karls-Universitat Heidelberg. Active years: 2018-2019.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 72 
1 out of 64 
Years Active: 2018-2019
Title: Xian Zhang: Innovator in Biomarker Research
Introduction
Xian Zhang is a prominent inventor based in Heidelberg, Germany. He has made significant contributions to the field of biomarker research, particularly in relation to drug response in cancer treatment. With a total of 2 patents, his work is paving the way for advancements in personalized medicine.
Latest Patents
Xian Zhang's latest patents focus on the use of BUBR1 as a biomarker for predicting drug response to furazanobenzimidazoles. His innovative approach aims to identify resistance to diseases such as cancer in subjects, utilizing a compound of general formula (I). This research holds promise for improving treatment outcomes for patients.
Career Highlights
Throughout his career, Xian Zhang has worked with notable organizations, including Basilea Pharmaceutica AG and Ruprecht-Karls-Universität Heidelberg. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Xian has collaborated with esteemed colleagues such as Heidi Alexandra Lane and Felix Bachmann. These partnerships have enhanced his research efforts and expanded the impact of his work in the scientific community.
Conclusion
Xian Zhang's contributions to biomarker research and his innovative patents are significant in the fight against cancer. His work exemplifies the importance of research in developing effective treatments for complex diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile